Safety and outcomes of open-label deferasirox iron chelation therapy for mucormycosis

Brad Spellberg; David Andes; Mario Perez; Anne Anglim; Hector Bonilla; Glenn E. Mathisen; Thomas J. Walsh; Ashraf S. Ibrahim

doi:10.1128/AAC.00361-09

Safety and outcomes of open-label deferasirox iron chelation therapy for mucormycosis

Brad Spellberg, David Andes, Mario Perez, Anne Anglim, Hector Bonilla, Glenn E. Mathisen, Thomas J. Walsh, Ashraf S. Ibrahim

Research output: Contribution to journal › Article › peer-review

70 Scopus citations

Abstract

We sought to describe the safety profile of open-label, adjunctive deferasirox iron chelation therapy in eight patients with biopsy-proven mucormycosis. Deferasirox was administered for an average of 14 days (range, 7 to 21) at 5 to 20 mg/kg of body weight/day. The only adverse effects attributable to deferasirox were rashes in two patients. Deferasirox treatment was not associated with changes in renal or liver function, complete blood count, or transplant immunosuppressive levels. Thus, deferasirox appears safe as an adjunctive therapy for mucormycosis.

Original language	English (US)
Pages (from-to)	3122-3125
Number of pages	4
Journal	Antimicrobial agents and chemotherapy
Volume	53
Issue number	7
DOIs	https://doi.org/10.1128/AAC.00361-09
State	Published - Jul 2009
Externally published	Yes

ASJC Scopus subject areas

Pharmacology
Pharmacology (medical)
Infectious Diseases

Access to Document

10.1128/AAC.00361-09

Cite this

@article{82efb5f28d4b4e3b86a0964a2cbf50a6,

title = "Safety and outcomes of open-label deferasirox iron chelation therapy for mucormycosis",

abstract = "We sought to describe the safety profile of open-label, adjunctive deferasirox iron chelation therapy in eight patients with biopsy-proven mucormycosis. Deferasirox was administered for an average of 14 days (range, 7 to 21) at 5 to 20 mg/kg of body weight/day. The only adverse effects attributable to deferasirox were rashes in two patients. Deferasirox treatment was not associated with changes in renal or liver function, complete blood count, or transplant immunosuppressive levels. Thus, deferasirox appears safe as an adjunctive therapy for mucormycosis.",

author = "Brad Spellberg and David Andes and Mario Perez and Anne Anglim and Hector Bonilla and Mathisen, {Glenn E.} and Walsh, {Thomas J.} and Ibrahim, {Ashraf S.}",

year = "2009",

month = jul,

doi = "10.1128/AAC.00361-09",

language = "English (US)",

volume = "53",

pages = "3122--3125",

journal = "Antimicrobial agents and chemotherapy",

issn = "0066-4804",

publisher = "American Society for Microbiology",

number = "7",

}

TY - JOUR

T1 - Safety and outcomes of open-label deferasirox iron chelation therapy for mucormycosis

AU - Spellberg, Brad

AU - Andes, David

AU - Perez, Mario

AU - Anglim, Anne

AU - Bonilla, Hector

AU - Mathisen, Glenn E.

AU - Walsh, Thomas J.

AU - Ibrahim, Ashraf S.

PY - 2009/7

Y1 - 2009/7

N2 - We sought to describe the safety profile of open-label, adjunctive deferasirox iron chelation therapy in eight patients with biopsy-proven mucormycosis. Deferasirox was administered for an average of 14 days (range, 7 to 21) at 5 to 20 mg/kg of body weight/day. The only adverse effects attributable to deferasirox were rashes in two patients. Deferasirox treatment was not associated with changes in renal or liver function, complete blood count, or transplant immunosuppressive levels. Thus, deferasirox appears safe as an adjunctive therapy for mucormycosis.

AB - We sought to describe the safety profile of open-label, adjunctive deferasirox iron chelation therapy in eight patients with biopsy-proven mucormycosis. Deferasirox was administered for an average of 14 days (range, 7 to 21) at 5 to 20 mg/kg of body weight/day. The only adverse effects attributable to deferasirox were rashes in two patients. Deferasirox treatment was not associated with changes in renal or liver function, complete blood count, or transplant immunosuppressive levels. Thus, deferasirox appears safe as an adjunctive therapy for mucormycosis.

UR - http://www.scopus.com/inward/record.url?scp=67649935369&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67649935369&partnerID=8YFLogxK

U2 - 10.1128/AAC.00361-09

DO - 10.1128/AAC.00361-09

M3 - Article

C2 - 19433555

AN - SCOPUS:67649935369

SN - 0066-4804

VL - 53

SP - 3122

EP - 3125

JO - Antimicrobial agents and chemotherapy

JF - Antimicrobial agents and chemotherapy

IS - 7

ER -

Safety and outcomes of open-label deferasirox iron chelation therapy for mucormycosis

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this